Please login to the form below

Not currently logged in
Email:
Password:

Bydureon

This page shows the latest Bydureon news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

The new once-weekly formulation called Bydureon BCise uses a new simpler injection device, and was approved in the US in October. ... Sales of Bydureon shrank 2% in the first half of 2018, thanks to a combination of US pricing pressure and growing

Latest news

More from news
Approximately 2 fully matching, plus 41 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    150. AstraZeneca (UK). 3SBio. Distribution. Byetta, Bydureon (exanatide) for Type 2 diabetes in China.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics